MI HB4789

Expands Michigan's "right to try act" beyond terminal patients to include those with "life-threatening or severely debilitating illness" where death likelihood is high, the outcome is potentially fatal, or the condition causes major irreversible morbidity

Creates new category of "individualized investigational treatment" covering personalized therapies based on a patient's own genomic sequence, DNA, RNA, genes, or metabolites, including individualized gene therapy antisense oligonucleotides and neoantigen vaccines

Allows manufacturers operating within eligible facilities (institutions with federal human subjects protection assurances) to provide individualized investigational treatments to eligible patients, either free or at cost

Protects health care providers from license revocation or disciplinary action based solely on recommending or providing investigational drugs, biological products, devices, or individualized investigational treatments

Clarifies that health insurers, government agencies, and hospitals are not required to cover costs of experimental treatments, and shields manufacturers and caregivers from private lawsuits if they comply in good faith with the act